Lecanemab: looking before we leap
Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and
Drug Administration approval for the treatment of mild dementia due to Alzheimer disease …
Drug Administration approval for the treatment of mild dementia due to Alzheimer disease …
Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis
Background This systematic review assesses the likelihood of developing dementia and
cognitive impairment in patients with atrial fibrillation (AF) receiving non-vitamin K antagonist …
cognitive impairment in patients with atrial fibrillation (AF) receiving non-vitamin K antagonist …
[HTML][HTML] Oral anticoagulant therapy in older adults
J Stuby, M Haschke, T Tritschler, D Aujesky - Thrombosis research, 2024 - Elsevier
Patients aged≥ 65 years not only account for the majority of patients with atrial fibrillation
(AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity …
(AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity …